Since the beginning of the COVID-19 pandemic we have witnessed the global response of governments and their efforts to protect the public and healthcare services. Naturally, this means that the need for reliable testing methods has been overwhelming, initially this was via PCR testing facilities and as the government approach evolved, the need for lateral flow devices emerged.

Lateral flow or ‘rapid’ devices are an easy to use, scalable method that deliver results in under 30 minutes and they have played a key part in the UK governments’ roadmap to easing COVID-19 restrictions. Regular rapid testing programmes have been implemented in schools, hospitals, care homes and workplaces with the aim to detect cases both in the early stages of infection and asymptomatic infections to help reduce infection transmission rates in communities and enable some aspects of normal life to resume.

For many people, rapid testing has become a routine part of life, however, news articles in recent weeks have reported concerns over the accuracy of lateral flow tests from some manufacturers. This only further highlights the importance of accurate tests that have proven high levels of precision and reliability.

Biorex Diagnostics manufacture a range of lateral flow tests for the detection of COVID-19. With a core focus on quality, the team at Biorex have developed a COVID-19 antigen test that offers reliable results for Sars-CoV-2. Antigen is generally detectable in the upper respiratory specimens during the acute phase of infection and an early diagnosis will help healthcare professionals treat and control the disease effectively.

Benefits of the Biorex Coronavirus Ag Rapid Test

• Delivers results in 15 minutes
• Over 98% accuracy*
• CE Marked
• Validated by Porton Down on Nasal (anterior nares) samples
• MHRA Registered
• Easy to use method with all necessary reagents provided

To find out more about the range of COVID-19 tests available contact info@biorexdiagnostics.com

*Accuracy levels have been assessed using two sample types; 99.42% via nasopharyngeal sample and 98.73% via nasal sample.